Lasers to Aid in Treatment of Acne Scars

Launched by GOLDMAN, BUTTERWICK, FITZPATRICK AND GROFF · Oct 11, 2022

Keywords

ClinConnect Summary

The primary objective of this clinical trial is to assess efficacy and safety of combination treatment with fractional picosecond 755nm Alexandrite laser with focused lens array (Picosure®, Cynosure, Westford, MA) and radiofrequency microneedling (Potenza™, Cynosure, Westford, MA) for treatment of facial, atrophic acne scarring.

Enrolled subjects will be randomized to receive picosecond 755 nm Alexandrite laser treatment to either the left or right facial half. The subjects will then undergo full face radiofrequency microneedling (RFM).

Subjects satisfying all inclusion and no exclusion c...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult males and females aged 18 or older
• • Subjects in good general health based on investigator's judgment and medical history
• • Moderate to severe atrophic acne scarring on the face per ECCA (échelle d'évaluation clinique des cicatrices d'acné) acne grading scale
• • Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study
• • Understands and accepts the obligation and is logistically able to be present for all visits
• • Is willing to comply with all requirements of the study and sign the informed consent documents
• • Must be willing to maintain usual sun exposure for the duration of the study
• • Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study
• • Negative urine pregnancy test result at the time of study entry (if applicable)
• • For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.
• • 1. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
• • 2. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and/or vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active.
• Exclusion Criteria:
• • Female subjects who are pregnant, planning a pregnancy, or breast feeding during the study
• • The subject is hypersensitive to light in the near infrared wavelength region
• • The subject is taking medication which is known to increase sensitivity to sunlight
• • The subject has a seizure disorders triggered by light
• • The subject is receiving or have received gold therapy
• • The subject has a pacemaker
• • The subject has a metal implant that interferes with the transmission of energy to the electrical field
• • The subject has any embedded electronic devices that give or receive a signal such as Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant
• • Gold allergy
• • The subject has nerve insensitivity to heat in the treatment area or in the neutral pad placement area or a neuropathic disorder
• • The subject has severe laxity or sagging that causes redundant folds of tissue or hanging skin in the area to be treated
• • Dermal fillers, neuromodulator, biostimulatory injectables, fat grafting, radiofrequency device treatments, microfocused ultrasound device treatments, laser and light-based device treatments, microneedling to the face during the 6-month period before study treatment m) Subjects with tattoos in the treatment areas n) Subjects with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study
• • Subjects with a history of or presence of any skin condition/disease (including but not limited to any visible rash, atopic dermatitis, psoriasis, actinic keratoses, keratinocyte carcinoma, melanoma, etc.) in the treatment area that might interfere with the diagnosis or evaluation of study parameters
• • History of keloid or hypertrophic scarring
• • Subjects with an active bacterial, viral, or fungal infection of the treatment areas
• • The subject has a significant systemic illness, such as lupus, or an illness localized in area being treated
• • History of lidocaine sensitivity deemed by the investigator to preclude the subject from enrolling into the study
• • Subjects planning any cosmetic procedure to the treatment areas during the study period, other than the treatment that will be performed by the investigator
• • Presence of incompletely healed wound(s) in the treatment area
• • Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study